Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer

Abstract Cobas EGFR mutation Test v2 was FDA-approved as qualitative liquid biopsy for actionable EGFR variants in non-small cell lung cancer (NSCLC). It generates semiquantitative index (SQI) values that correlate with mutant allele levels, but decision thresholds for clinical use in NSCLC surveill...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jonas Claus, Dieter De Smet, Joke Breyne, Janusz Wesolowski, Ulrike Himpe, Ingel Demedts, Geert A. Martens
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2024-08-01
coleção:	Scientific Reports
Assuntos:	Diagnostic techniques and procedures Clinical laboratory techniques Liquid biopsy Circulating tumor DNA Biomarkers Tumor
Acesso em linha:	https://doi.org/10.1038/s41598-024-68350-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!